The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
EORTC 22071-24071: Randomized, phase III trial of EGFR-antibody combined with adjuvant chemoradiation for patients with head and neck squamous cell carcinoma (HNSCC) at high risk of recurrence.
C. Liberatoscioli
No relevant relationships to disclose
J. A. Langendijk
Consultant or Advisory Role - Merck Serono (U)
C. Van Herpen
No relevant relationships to disclose
L. Collette
No relevant relationships to disclose
E. M. Ozsahin
No relevant relationships to disclose
R. Karra Gurunath
No relevant relationships to disclose
D. A. Lacombe
No relevant relationships to disclose
A. Gulyban
No relevant relationships to disclose
N. Gosselin
No relevant relationships to disclose
W. Budach
No relevant relationships to disclose